Many clinical trials have revealed that anti-PD-1/PD-L1 therapy is effective against various types of tumors, including malignant melanoma, non-small cell lung cancer, and renal cell carcinoma [7, 8]. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.